Overview
- TickerGALT on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersNorcross, United States2
- Incorporated inNV3
- Business address4960 Peachtree Industrial Boulevard, Suite 240, Norcross, Ga 300713
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI5299004HFYSAZM2ALW852
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered address701 S CARSON ST STE 200, 89701 Carson City, United States2
- Registered withBusiness Center (Secretary of State), NV200111970782
See how the biggest companies compare on our leaderboards
Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3’s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene “knocked-out” can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in MASH patients. We have completed two Phas…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.11
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $14.3M | $36.6M |
| General and administrative | $5.8M | $5.9M |
| Total operating expenses | $20.1M | $42.4M |
| Total operating loss | -$20.1M | -$42.4M |
| Interest income | $126.0K | $338.0K |
| Interest expense | -$7.3M | -$5.5M |
| Change in fair value of derivatives | -$3.5M | $588.0K |
| Total other expense | -$10.8M | -$4.6M |
| Net loss | -$30.8M | -$47.0M |
| Preferred stock dividends | -$138.0K | -$153.0K |
| Net loss applicable to common stockholders | -$31.0M | -$47.2M |
| Net loss per common share - basic (in Dollars per share) | -$0.48 | -$0.76 |
| Net loss per common share - diluted (in Dollars per share) | -$0.48 | -$0.76 |
| Weighted average common and potential common shares outstanding - basic (in Shares) | 63.9M shares | 62.3M shares |
| Weighted average common and potential common shares outstanding - diluted (in Shares) | 63.9M shares | 62.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.11
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.7M | $15.1M | |
| Prepaid expenses and other current assets | $1.7M | $2.1M | |
| Total current assets | $19.4M | $17.3M | |
| Other | $96.0K | $243.0K | |
| Total assets | $19.5M | $17.5M | |
| Accounts payable | $3.2M | $5.7M | |
| Accrued expenses | $4.7M | $8.2M | |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $0 | $21.1M | |
| Current portion of derivative liabilities (Note 6) | $0 | $369.0K | |
| Accrued dividends payable | $63.0K | $63.0K | |
| Total current liabilities | $8.0M | $35.4M | |
| Convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $32.7M | $10.7M | |
| Derivative liabilities (Note 6) | $4.0M | $47.0K | |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (Note 10) | $101.0M | $74.4M | |
| Total liabilities | $145.7M | $120.6M | |
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2025 and 2024, redemption value: $7,966,000, liquidation value: $1,760,000 at December 31, 2025 | $1.7M | $1.7M | $1.7M |
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2025 and 2024, 20,000,000 shares designated at December 31, 2025 and 2024, respectively | $0 | $0 | |
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at December 31, 2025 and 2024, respectively, liquidation value $1,210,000 at December 31, 2025 | $490.0K | $500.0K | |
| Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at December 31, 2025 and 2024, respectively | $65.0K | $62.0K | |
| Additional paid-in capital | $304.1M | $296.2M | |
| Accumulated deficit | -$432.5M | -$401.6M | |
| Total stockholders deficit | -$127.9M | -$104.8M | -$62.0M |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | $19.5M | $17.5M | |
| Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in Shares) | 1.0K shares | 1.0K shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares issued (in Shares) | 176 shares | 176 shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in Shares) | 176 shares | 176 shares | 176 shares |
| Series C 6% super dividend redeemable convertible preferred stock, redemption value | $8.0B | ||
| Series C 6% super dividend redeemable convertible preferred stock liquidation value | $1.8B | ||
| Undesignated stock, par value (in Dollars per share) | $0 | $0 | |
| Undesignated stock, shares authorized (in Shares) | 20.0M shares | 20.0M shares | |
| Undesignated stock, shares designated (in Shares) | 20.0M shares | 20.0M shares | |
| Series A 12% convertible preferred stock, shares authorized (in Shares) | 1.7M shares | 1.7M shares | |
| Series A 12% convertible preferred stock, shares issued (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, shares outstanding (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, liquidation value | $1.2B | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, issued (in Shares) | 65.2M shares | 63.2M shares | |
| Common stock, outstanding (in Shares) | 65.2M shares | 63.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $17.7M | $15.1M | |
| Prepaid expenses and other current assets | $1.7M | $2.1M | |
| Total current assets | $19.4M | $17.3M | |
| Other | $96.0K | $243.0K | |
| Total assets | $19.5M | $17.5M | |
| Accounts payable | $3.2M | $5.7M | |
| Accrued expenses | $4.7M | $8.2M | |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $0 | $21.1M | |
| Current portion of derivative liabilities (Note 6) | $0 | $369.0K | |
| Accrued dividends payable | $63.0K | $63.0K | |
| Total current liabilities | $8.0M | $35.4M | |
| Convertible notes payable and accrued interest, net of debt discounts related party (Note 5) | $32.7M | $10.7M | |
| Derivative liabilities (Note 6) | $4.0M | $47.0K | |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (Note 10) | $101.0M | $74.4M | |
| Total liabilities | $145.7M | $120.6M | |
| Series C 6% super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 issued and outstanding at December 31, 2025 and 2024, redemption value: $7,966,000, liquidation value: $1,760,000 at December 31, 2025 | $1.7M | $1.7M | $1.7M |
| Undesignated stock, $0.01 par value; 20,000,000 shares authorized at December 31, 2025 and 2024, 20,000,000 shares designated at December 31, 2025 and 2024, respectively | $0 | $0 | |
| Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,210,000 and 1,235,000 issued and outstanding at December 31, 2025 and 2024, respectively, liquidation value $1,210,000 at December 31, 2025 | $490.0K | $500.0K | |
| Common stock, $0.001 par value; 150,000,000 shares authorized at December 31, 2025 and 2024, 65,201,995 and 63,157,235 issued and outstanding at December 31, 2025 and 2024, respectively | $65.0K | $62.0K | |
| Additional paid-in capital | $304.1M | $296.2M | |
| Accumulated deficit | -$432.5M | -$401.6M | |
| Total stockholders deficit | -$127.9M | -$104.8M | -$62.0M |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | $19.5M | $17.5M | |
| Series C 6% super dividend redeemable convertible preferred stock, shares authorized (in Shares) | 1.0K shares | 1.0K shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares issued (in Shares) | 176 shares | 176 shares | |
| Series C 6% super dividend redeemable convertible preferred stock, shares outstanding (in Shares) | 176 shares | 176 shares | 176 shares |
| Series C 6% super dividend redeemable convertible preferred stock, redemption value | $8.0B | ||
| Series C 6% super dividend redeemable convertible preferred stock liquidation value | $1.8B | ||
| Undesignated stock, par value (in Dollars per share) | $0 | $0 | |
| Undesignated stock, shares authorized (in Shares) | 20.0M shares | 20.0M shares | |
| Undesignated stock, shares designated (in Shares) | 20.0M shares | 20.0M shares | |
| Series A 12% convertible preferred stock, shares authorized (in Shares) | 1.7M shares | 1.7M shares | |
| Series A 12% convertible preferred stock, shares issued (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, shares outstanding (in Shares) | 1.2M shares | 1.2M shares | |
| Series A 12% convertible preferred stock, liquidation value | $1.2B | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 150.0M shares | 150.0M shares | |
| Common stock, issued (in Shares) | 65.2M shares | 63.2M shares | |
| Common stock, outstanding (in Shares) | 65.2M shares | 63.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.11
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$30.8M | -$47.0M |
| Amortization of right to use asset | $53.0K | $37.0K |
| Stock-based compensation expense | $1.7M | $2.4M |
| Non-cash interest expense | $1.1M | $1.1M |
| Change in fair value of derivatives | $3.5M | -$588.0K |
| Prepaid expenses and other assets | $416.0K | -$82.0K |
| Accrued interest on convertible notes payable and convertible line of credit related party | $6.2M | $4.4M |
| Accounts payable, accrued expenses and other liabilities | -$6.0M | -$2.1M |
| Net cash from operating activities | -$23.9M | -$41.8M |
| Net cash from investing activities | $0 | $0 |
| Net proceeds from convertible line of credit related party | $21.0M | $30.0M |
| Net proceeds from issuance of common stock | $3.2M | $0 |
| Net proceeds from exercise of common stock options and warrants | $2.2M | $1.2M |
| Net cash from financing activities | $26.5M | $31.2M |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | $2.6M | -$10.5M |
| Payment of preferred stock dividends in common stock | $138.0K | $91.0K |
| Common stock purchase warrants issued in connection with related party line of credit | $667.0K | $845.0K |
| Noncash right to use lease asset | $61.0K | $0 |
| Conversion of Series A preferred to common stock | $10.0K | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
GALECTIN THERAPEUTICS INC sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of GALECTIN THERAPEUTICS INC
- Richard E. Uihlein Filed SCHEDULE 13D/A on GALECTIN THERAPEUTICS INC, latest Aug 4, 2026
- 10X Fund, L.P. Filed SC 13D/A on GALECTIN THERAPEUTICS INC, latest Dec 1, 2023
- GALECTIN THERAPEUTICS INC Norcross, Georgia, United States
- Galectin Sciences LLC Subsidiary · Georgia, United States
- Galectin Therapeutics Security Corp. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What GALECTIN THERAPEUTICS INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $74.0K11 Dec 31, 2025 | $74.0K11 Dec 31, 2024 | 0% |
| Accumulated depreciation | $74.0K11 Dec 31, 2025 | $74.0K11 Dec 31, 2024 | 0% |
| Property and equipment, net | $011 Dec 31, 2025 | $011 Dec 31, 2024 | |
| Operating-lease assets (leased space) | $22.0K11 Dec 31, 2025 | $16.0K10 Dec 31, 2024 | +37.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $17.7M11 Dec 31, 2025 | $15.1M11 Dec 31, 2024 | +17.2% |
Properties, in its own words
Properties
We lease 3,610 square feet for our executive offices located at 4960 Peachtree Industrial Blvd., Norcross, GA. We also lease on a month-to-month basis approximately 300 square feet in Natick, MA, for use by research and development employees and which is collocated with one of our research and development service vendors. We believe these spaces are suitable for our present operations.
Item 2 of the 10-K filed Mar 31, 2026.5
Leadership
Who has led GALECTIN THERAPEUTICS INC, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2010201520202025
- Chief executive officerHarold H. Shlevin Jun 18, 2018 to Jan 13, 202014
- Chief executive officerPeter G. Traber May 31, 2011 to Jun 15, 201815
- Chief executive officerTheodore Daniel Zucconi Feb 18, 2009 to May 28, 200916
- ChairJames C. Czirr Jun 30, 2011 to Feb 3, 201517
- PresidentPeter G. Traber May 31, 2011 to Jun 15, 201815
- PresidentTheodore Daniel Zucconi Dec 21, 2007 to Mar 26, 200918
- Chief financial officerJack W. Callicutt Jul 2, 2013 to now19
- Chief financial officerThomas McGauley May 25, 2012 to Jun 21, 201320
- Chief financial officerAnthony Don Squeglia Nov 9, 2007 to Feb 3, 201021
- Chief financial officerCarl Laurence Lueders Mar 13, 2006 to Mar 13, 200722
- Chief operating officerHarold H. Shlevin Aug 29, 2012 to Jun 14, 201823
- Chief operating officerMaureen Foley Mar 13, 2006 to Feb 3, 201024
Board members and other officers (27)
- Chief Medical OfficerKhurram Jamil Aug 5, 2024 to now25
- Chief Medical OfficerPol F. Boudes Mar 16, 2020 to Feb 7, 202426
- Ex. VP, Mfg. & Product Dev.Eliezer Zomer Mar 13, 2006 to Apr 24, 200927
- Board memberHenry Brem Mar 17, 2026 to now28
- Board memberBenjamin Carson Sr. Feb 7, 2024 to now29
- Board memberElissa J. Schwartz Mar 31, 2021 to now30
- Board memberRichard A. Zordani Jr. Mar 31, 2021 to now31
- Board memberHarold H. Shlevin Jan 13, 2020 to now32
- Board memberKary Eldred May 29, 2018 to now33
- Board memberHerman Paul Pressler Jun 3, 2011 to Jul 8, 201534
- Board memberJohn F. Mauldin Jun 3, 2011 to Dec 19, 201635
- Board memberKevin D. Freeman Jun 3, 2011 to now36
- Board memberMarc Rubin Oct 14, 2011 to Jan 27, 202537
- Board memberPeter G. Traber Feb 20, 2009 to Dec 6, 201638
- Board memberRod D. Martin Feb 20, 2009 to Jul 8, 201539
- Board memberJames C. Czirr Feb 25, 2009 to Dec 1, 202340
- Board memberArthur Greenberg Aug 26, 2009 to Dec 19, 201641
- Board memberJames Theophile Gourzis Feb 9, 2007 to Feb 11, 200942
- Board memberHenry Jemil Esber Mar 2, 2007 to Feb 11, 200943
- Board memberSydney Colin Neill Aug 24, 2007 to Jun 29, 201144
- Board memberTheodore Daniel Zucconi Sep 27, 2007 to Apr 18, 201845
- Board memberBurton C. Firtel Mar 13, 2006 to Mar 13, 200746
- Board memberDale H. Conaway Mar 13, 2006 to Feb 11, 200947
- Board memberEdgar Ben-Josef Mar 13, 2006 to Mar 13, 200648
- Board memberJerald K. Rome Mar 13, 2006 to Apr 1, 201349
- Board memberMildred S. Christian Mar 13, 2006 to Feb 27, 200950
- Board memberSteven Prelack Mar 13, 2006 to Dec 19, 201651
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- PRO PHARMACEUTICALS INCSep 7, 2001 to May 26, 20113
Timeline
- Aug 14, 20268-K Results of operations52
- Aug 4, 20268-K Unregistered sale of shares53
- Jun 23, 20268-K Regulation FD disclosure54
- May 15, 20268-K Results of operations55
- Mar 31, 20268-K Results of operations56
- Mar 17, 20268-K Executive or director change57
- Jan 21, 20268-K Executive or director change58
- Jan 12, 20268-K Executive or director change59
- Dec 19, 20258-K Entered a material agreement60
- Dec 8, 20258-K Shareholder vote61
- Dec 3, 20258-K Regulation FD disclosure62
- Nov 14, 20258-K Results of operations63
- Jun 18, 2018New chief executive Harold H. Shlevin becomes CEO14
- May 31, 2011New chief executive Peter G. Traber becomes CEO15
- Feb 18, 2009New chief executive Theodore Daniel Zucconi becomes CEO16
Calendar
Coming up
- Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.13) a share, on Nov 14, 2025.64
When it reported results
- Aug 14, 2026Reported quarterly or annual results52
- May 15, 2026Reported quarterly or annual results55
- Mar 31, 2026Reported quarterly or annual results56
- Nov 14, 2025Reported quarterly or annual results63
- Aug 14, 2025Reported quarterly or annual results65
- May 15, 2025Reported quarterly or annual results66
- Mar 31, 2025Reported quarterly or annual results67
- Nov 14, 2024Reported quarterly or annual results68
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
355 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 225 insider forms, 2 large holders, 52 other. The latest 20:
- Oct 13, 2026ARS EDGAR
- Oct 13, 2026DEFA14A EDGAR
- Oct 13, 2026DEF 14A EDGAR
- Oct 2, 2026PRE 14A EDGAR
- Aug 14, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 4, 2026SCHEDULE 13D/A EDGAR
- Aug 4, 20268-K CURRENT REPORT FILING EDGAR
- Aug 4, 20264 EDGAR
- Jul 16, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 30, 20264 EDGAR
- Jun 29, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 26, 2026144 EDGAR
- Jun 25, 20264 EDGAR
- Jun 23, 2026144 EDGAR
- Jun 23, 20268-K EDGAR
- May 28, 20264 EDGAR
- May 15, 20268-K EDGAR
The 355 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
105 open-market trades by officers, directors and large owners since October 2021: 44 buys and 61 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 14, 2026 | Jamil KhurramChief Medical Officer | Sale | 16,250 | $5.13 | $83.4K | Form 4 |
| Jun 29, 2026 | Shlevin Harold H.Director | Sale | 22,268 | $5.04 | $112.2K | Form 4 |
| Jun 29, 2026 | Jamil KhurramChief Medical Officer | Sale | 47,467 | $5.04 | $239.2K | Form 4 |
| Jun 26, 2026 | Shlevin Harold H.Director | Sale | 7,732 | $5.00 | $38.7K | Form 4 |
| Jun 26, 2026 | Jamil KhurramChief Medical Officer | Sale | 4,570 | $5.00 | $22.9K | Form 4 |
| Jun 23, 2026 | Jamil KhurramChief Medical Officer | Sale | 7,557 | $3.14 | $23.7K | Form 4 |
| May 26, 2026 | Jamil KhurramChief Medical Officer | Sale | 568 | $3.10 | $1.8K | Form 4 |
| Feb 6, 2026 | ELDRED KARYDirector | Buy | 300 | $2.70 | $810 | Form 4 |
| Jan 6, 2026 | LEWIS JOELPresident and CEO | Sale | 37,698 | $3.58 | $135.0K | Form 4 |
| Jan 6, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 20,354 | $3.67 | $74.7K | Form 4 |
| Jan 6, 2026 | Jamil KhurramChief Medical Officer | Sale | 21,446 | $3.65 | $78.3K | Form 4 |
| Jan 5, 2026 | LEWIS JOELPresident and CEO | Sale | 27,731 | $3.91 | $108.4K | Form 4 |
| Jan 5, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 25,732 | $3.90 | $100.4K | Form 4 |
| Jan 5, 2026 | Jamil KhurramChief Medical Officer | Sale | 25,499 | $3.90 | $99.4K | Form 4 |
| Jan 2, 2026 | LEWIS JOELPresident and CEO | Sale | 18,571 | $4.20 | $78.0K | Form 4 |
| Jan 2, 2026 | CALLICUTT JACK WChief Financial Officer | Sale | 13,914 | $4.20 | $58.4K | Form 4 |
| Jan 2, 2026 | Jamil KhurramChief Medical Officer | Sale | 13,055 | $4.20 | $54.8K | Form 4 |
| Dec 31, 2025 | Jamil KhurramChief Medical Officer | Sale | 8,125 | $4.07 | $33.1K | Form 4 |
| Dec 23, 2025 | FREEMAN KEVIN DDirector | Buy | 5,500 | $3.55 | $19.5K | Form 4 |
| Dec 23, 2025 | FREEMAN KEVIN DDirector | Buy | 5,500 | $3.55 | $19.5K | Form 4 |
All 105 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Richard E. UihleinSCHEDULE 13D/A, 1 filing Aug 4, 202669
- 10X Fund, L.P.SC 13D/A, 1 filing Dec 1, 202370
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Joel LewisChief Executive Officer & President | 56 | $624.0K | $1.2M71 |
| 2025 | Khurram Jamil, M.D.Chief Medical Officer | $500.0K | $1.1M71 | |
| 2025 | Jack W. CallicuttChief Financial Officer | $400.0K | $806.6K71 | |
| 2024 | Joel LewisChief Executive Officer & President | 56 | $620.2K | $1.2M71 |
| 2024 | Khurram Jamil, M.D.Chief Medical Officer | $365.9K | $945.8K71 | |
| 2024 | Jack W. CallicuttChief Financial Officer | $397.3K | $716.9K71 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 98. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 2,988,353 | $13.9M | 0.0% | +2,189,116 |
| Vanguard Capital Management LLC | 2,168,065 | $10.1M | 0.0% | +201,523 |
| Geode Capital Management, LLC | 1,308,394 | $6.1M | 0.0% | +695,608 |
| Osaic Holdings, Inc. | 1,203,725 | $5.6M | 0.0% | +81,055 |
| Marshall Wace, Llp | 831,010 | $3.9M | 0.0% | −388,902 |
| Wealthspire Advisors, LLC | 721,788 | $3.3M | 0.0% | No change |
| State Street Corp | 567,779 | $2.6M | 0.0% | +309,347 |
| Commonwealth Equity Services, LLC | 407,113 | $1.9M | 0.0% | +40,000 |
| Northern Trust Corp | 386,545 | $1.8M | 0.0% | +256,097 |
| Vanguard Fiduciary Trust Co | 366,476 | $1.7M | 0.0% | +62,235 |
| Vanguard Portfolio Management LLC | 327,766 | $1.5M | 0.0% | New |
| Two Sigma Investments, LP | 318,245 | $1.5M | 0.0% | −148,818 |
| LPL Financial LLC | 285,380 | $1.3M | 0.0% | +18,180 |
| Geneos Wealth Management Inc. | 240,427 | $1.1M | 0.0% | −500 |
| UBS Group AG | 219,319 | $1.0M | 0.0% | +39,578 |
| Retirement Guys Formula LLC | 211,053 | $979.3K | 0.4% | +23,991 |
| Citadel Advisors LLC | 198,701 | $922.0K | 0.0% | −91,659 |
| Sovran Advisors, LLC | 257,997 | $874.6K | 0.1% | +167 |
| Susquehanna International Group, Llp | 177,197 | $822.2K | 0.0% | −378,505 |
| National Bank Of Canada /fi/ | 167,900 | $779.1K | 0.0% | New |
| Blair William & Co/il | 149,283 | $692.7K | 0.0% | No change |
| Charles Schwab Investment Management Inc | 116,424 | $540.2K | 0.0% | +86,414 |
| Bank of New York Mellon Corp | 105,742 | $490.6K | 0.0% | New |
| HighTower Advisors, LLC | 94,125 | $436.7K | 0.0% | +750 |
| Morgan Stanley | 93,475 | $433.7K | 0.0% | −10,930 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How GALECTIN THERAPEUTICS INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARGALECTIN THERAPEUTICS INC1
- CIK0001133416
- Employer ID (EIN)04-35623255
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inNevada5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 300711
- Phone678-620-31861
- Shares outstanding100,849,644 as of Aug 6, 202613
- Public float$109.0M as of Jun 30, 20255
- AuditorCherry Bekaert LLP, Atlanta, Georgia PCAOB ID 677; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceJun 13, 20011
- Filings1,578 in all: 4 (669), 8-K (361), 10-Q (68), 4/A (39), 424B3 (38), 3 (35), SC 13D/A (34), 144 (25)1
All 58 form types
5 (25), 10-K (24), DEF 14A (24), UPLOAD (23), CORRESP (22), EFFECT (19), S-3 (19), PRE 14A (10), SC 13G/A (10), 8-K/A (9), POS AM (9), S-8 (9), 10QSB (8), SC 13G (7), REGDEX (6), S-3/A (6), DEFA14A (5), SC 13D (5), 10-K/A (4), 3/A (4), 424B5 (4), 5/A (4), ARS (4), CT ORDER (4), D (4), 10-Q/A (3), 25-NSE (3), NT 10-K (3), 10QSB/A (2), 10SB12G/A (2), 144/A (2), NT 10-Q (2), PRER14A (2), RW (2), S-1 (2), S-1/A (2), SB-2 (2), SB-2/A (2), 10KSB (1), 10SB12G (1), 424B1 (1), 424B2 (1), 8-A12B (1), 8-A12B/A (1), CERTAMX (1), CERTNAS (1), DEF 14C (1), FWP (1), NO ACT (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 31, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Oct 13, 2026
Latest 8-K (8-K) Aug 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 Par Value Per Share | GALT | NASDAQ |
From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks GALECTIN THERAPEUTICS INC names in Item 1A of its 10-K filed Mar 31, 2026: 38 risks under these headings, as written.5
- Risks Related to Our Company
- We have incurred net losses to date and must raise additional capital in order to continue to operate.
- We are significantly dependent on Mr. Uihlein for financing, and there is no assurance that he will continue to provide funding.
- Our NAVIGATE trial was our only active clinical trial.
- We have from time to time faced substantial doubt about our ability to continue as a going concern.
- We are a development stage company and have not yet generated any revenue.
- We are dependent on the success of our lead product candidate, belapectin, and we cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized.
- Even if we receive regulatory approval, we may be unable to commercialize our product candidates.
- We are dependent on third parties for clinical trial design, execution, and manufacturing, and their failure to perform could adversely affect our business.
- There are risks associated with our reliance on third parties for manufacturing belapectin.
- We are exposed to pre-clinical and clinical liability risks which could place a financial burden upon us, should we be sued, because we do not currently have product liability insurance beyond our general insurance coverage.
- We face intense competition in the biotechnology and pharmaceutical industries.
The other 27 risks
- The market for our proposed products is rapidly changing and competitive, and new drugs and new treatments that may be developed by others could impair our ability to maintain and grow our business and remain competitive.
- Our lack of operating experience may cause us difficulty in managing our growth.
- We depend on key individuals to develop our products and core technologies and pursue collaborative relationships.
- We may fail to comply with our reporting and other requirements under federal securities laws.
- We have identified a material weakness in our internal control over financial reporting, which, if not remediated, could result in material misstatements in our financial statements.
- Our long-term success is dependent not only upon the success of our trials but also upon us being able to capitalize upon potential positive results of our trials, which is not assured.
- We have previously been a defendant in a shareholder derivative action, and any possible future such lawsuits may adversely affect our business, financial condition, results of operations and cash flows.
- Risks Related to the Regulation of our Products
- We will need regulatory approvals to commercialize our products.
- Even if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory review. If we fail to comply with ongoing regulatory requirements, we could lose our approvals to market drugs, in which case our business would be materially adversely affected.
- The drug development process to obtain FDA approval is very costly and time consuming, and if we cannot complete our clinical trials in a cost-effective manner, our results of operations may be adversely affected.
- Clinical trial data may be negative, inconclusive, or subject to varying interpretations, and our product candidates may cause undesirable side effects, any of which could delay, limit, or prevent regulatory approval.
- Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.
- Risks Related to Our Intellectual Property
- Our competitive position depends upon protection of our intellectual property, and we may be unable to adequately protect our proprietary rights.
- We may incur substantial costs from intellectual property litigation, and we may be unable to protect or use our technology.
- Trademark registrations, confidentiality agreements, and trade secret protections may be inadequate to protect our intellectual property.
- Risks Related to Information Technology and Cybersecurity
- We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.
- Risks Related to Our Common Stock
- The market price of our common stock may be volatile and adversely affected by several factors. This could subject us to securities class action litigation, and our stockholders could incur substantial losses.
- Our board of directors has the power to designate, without stockholder approval, additional series of preferred capital, the shares of which could be senior to our common stock and be entitled to conversion or voting rights that adversely affect the holders of our common stock.
- Nevada law and our charter documents could make it more difficult for a third party to acquire us and discourage a takeover, which could depress the trading price of our common stock.
- We may issue additional common stock, which might dilute the net tangible book value per share of our common stock.
- A sale of a substantial number of shares of the common stock may cause the price of our common stock to decline.
- We have not paid cash dividends on our common stock in the past and do not expect to pay cash dividends in the foreseeable future.
- Our shares of common stock have been thinly traded, so you may be unable to sell at or near ask prices or even at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares.
- Concentration of ownership by our principal stockholders may limit your ability to influence the outcome of director elections and other transactions requiring stockholder approval.
- Richard E. Uihlein’s and 10X Fund’s significant ownership positions may deter or prevent efforts by other companies to acquire us, which could prevent our stockholders from realizing a control premium.
- Richard E. Uihlein and/or 10X Fund could sell or transfer a substantial number of shares of our common stock, which could depress the price of our securities or result in a change in control of our company.
- A pandemic similar to the COVID-19 pandemic could adversely impact our business, including our preclinical studies and clinical trials.
Legal proceedings
Legal Proceedings
From time to time, the Company is exposed to litigation relating to its operations. The Company is not currently engaged in any legal proceedings that are expected, individually or in the aggregate, to have a material, adverse effect on its financial condition or results of operations.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJames C. Czirr, Chair
- 18SEC EDGARTheodore Daniel Zucconi, President
- 19
- 20
- 21
- 22
- 23
- 24
- 25SEC EDGARKhurram Jamil, Chief Medical Officer
- 26SEC EDGARPol F. Boudes, Chief Medical Officer
- 27
- 28SEC EDGARHenry Brem, Board member
- 29SEC EDGARBenjamin Carson Sr., Board member
- 30SEC EDGARElissa J. Schwartz, Board member
- 31SEC EDGARRichard A. Zordani Jr., Board member
- 32SEC EDGARHarold H. Shlevin, Board member
- 33SEC EDGARKary Eldred, Board member
- 34SEC EDGARHerman Paul Pressler, Board member
- 35SEC EDGARJohn F. Mauldin, Board member
- 36SEC EDGARKevin D. Freeman, Board member
- 37SEC EDGARMarc Rubin, Board member
- 38SEC EDGARPeter G. Traber, Board member
- 39SEC EDGARRod D. Martin, Board member
- 40SEC EDGARJames C. Czirr, Board member
- 41SEC EDGARArthur Greenberg, Board member
- 42
- 43SEC EDGARHenry Jemil Esber, Board member
- 44SEC EDGARSydney Colin Neill, Board member
- 45
- 46SEC EDGARBurton C. Firtel, Board member
- 47SEC EDGARDale H. Conaway, Board member
- 48SEC EDGAREdgar Ben-Josef, Board member
- 49SEC EDGARJerald K. Rome, Board member
- 50SEC EDGARMildred S. Christian, Board member
- 51SEC EDGARSteven Prelack, Board member
- 52SEC EDGARResults of operations
- 53SEC EDGARUnregistered sale of shares
- 54SEC EDGARRegulation FD disclosure
- 55SEC EDGARResults of operations
- 56SEC EDGARResults of operations
- 57SEC EDGARExecutive or director change
- 58SEC EDGARExecutive or director change
- 59SEC EDGARExecutive or director change
- 60SEC EDGAREntered a material agreement
- 61SEC EDGARShareholder vote
- 62SEC EDGARRegulation FD disclosure
- 63SEC EDGARResults of operations
- 64NasdaqNasdaq calendar
- 65
- 66
- 67
- 68
- 69
- 70
- 71